The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders' concerns

被引：35

作者：

Cuende, Natividad ^{[1
]}

Boniface, Christelle ^{[2
]}

Bravery, Christopher ^{[3
]}

Forte, Miguel ^{[2
]}

Giordano, Rosaria ^{[4
]}

Hildebrandt, Martin ^{[5
]}

Izeta, Ander ^{[6
]}

Dominici, Massimo ^{[7
]}

机构：

[1] Junta Andalucia, Serv Andaluz Salud, Andalusian Initiat Adv Therapies, Seville, Spain

[2] TxCell SA, Valbonne, Sophia Antipoli, France

[3] Consulting Adv Biol Ltd, London, England

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[5] Tech Univ Munich, TUMCells Interdisciplinary Ctr Cellular Therapie, D-80290 Munich, Germany

[6] Hosp Univ Donostia, Inst Biodonostia, Tissue Engn Lab, San Sebastian, Spain

[7] Univ Hosp Modena & Reggio Emilia, Lab Cell Biol & Adv Canc Therapies, Modena, Italy

来源：

CYTOTHERAPY | 2014年 / 16卷 / 12期

关键词：

MARROW MONONUCLEAR-CELLS;

D O I：

10.1016/j.jcyt.2014.08.007

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

[No abstract available]

引用

页码：1597 / 1600

页数：4

共 50 条

[41] Advanced Therapy Medicinal Products - a Multiple Challenge
Pruss, Axel
Garritsen, Henk
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (06) : 384 - 385
[42] Revised guideline for advanced therapy medicinal products
Reactions Weekly, 2018, 1689 (1) : 4 - 4
[43] Clinical trials with advanced therapy medicinal products
Schuessler-Lenz, M.
Schneider, C. K.
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2010, 53 (01) : 68 - 74
[44] Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe
Farkas, Andreas M.
Mariz, Segundo
Stoyanova-Beninska, Violeta
Celis, Patrick
Vamvakas, Spiros
Larsson, Kristina
Sepodes, Bruno
FRONTIERS IN MEDICINE, 2017, 4
[45] Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective
Salmikangas, Paula
Schuessler-Lenz, Martina
Ruiz, Sol
Celis, Patrick
Reischl, Ilona
Menezes-Ferreira, Margarida
Flory, Egbert
Renner, Matthias
Ferry, Nicolas
REGULATORY ASPECTS OF GENE THERAPY AND CELL THERAPY PRODUCTS: A GLOBAL PERSPECTIVE, 2015, 871 : 103 - 130
[46] Challenges in development, market authorisation and commercialisation of advanced therapy medicinal products in Europe: A cohort study
ten Ham, ten Renske M. T.
Hoekman, Jarno
Hovels, Anke M.
Broekmans, Andre W.
Leufkens, Hubert G. M.
Klungel, Olaf H.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 428 - 428
[47] Advanced therapy medicinal products: new therapeutic class, new regulations and implications for the hospital staff
Trouvin, Jean-Hugues
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2013, 197 (02): : 531 - 533
[48] CURRENT REIMBURSEMENT SITUATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) IN GERMANY: WHICH STRATEGY TO SECURE ADEQUATE FUNDING?
Campion, M.
Bot, D.
Ecker, T.
VALUE IN HEALTH, 2016, 19 (07) : A441 - A441
[49] European regulatory experience with advanced therapy medicinal products
Barkholt, Lisbeth
Voltz-Girolt, Caroline
Raine, June
Salmonson, Tomas
Schuessler-Lenz, Martina
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (01) : 8 - +
[50] CURRENT DEVELOPMENTS IN THE REGULATION OF ADVANCED THERAPY MEDICINAL PRODUCTS
Ruiz, S.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 15 - 16

← 1 2 3 4 5 →